Abstract
Renin, it is now certain, plays an important role in a significant number of disorders, such as essential hypertension and diabetic hypertension in blacks. These disorders have been categorized along sharp renin lines: high, normal, and low renin subgroups (11,54). Renin initiates the cleavage of angiotensin I, which is subsequently converted to angiotensin II, a potent vasoconstrictor molecule that stimulates aldosterone and vasopressin secretion and salt and water retention. By initiating the cascade, renin is therefore a significant factor in the physiological manifestation of the renin—angiotensin—aldosterone system (RAAS). RAAS plays an important role in cardiovascular homeostasis and chemiosmotic (salt and water coupled to proton movement) balance, but renin secretion from the kidney is a key step in the system. There is general agreement that renin physiological inhibition (or its equivalent) provides rational therapeutic efficacy for high-renin essential hypertension (106). Calcium channel blockade has also been shown to provide satisfactory results, even in the low-renin subgroup where earlier therapeutic strategies have proven largely ineffective. In low-renin hypertension (LRH) and diabetic lowrenin hypertension (dLRH), characteristic of an increasing number of blacks, only recently has sufficient evidence been accumulated to target specific molecules controlling renin secretion at the cellular level, thereby opening the way for novel approaches to drug development. It is clear that calcium and chemiosmotic forces are central to the control of renin secretion and that the renin profiles observed in some renin disorders may reflect abnormal control at specific sites along the secretory cascade (33). This chapter surveys briefly the current state of knowledge in the low-renin subgroup, as it relates to renin and prorenin [(pro)Renin] processing, storage, and secretion. We also focus on theories of (pro)Renin secretion in an attempt to describe the sites of control (and thereby prime targets of abnormal function as evidenced by examples of lowrenin syndromes [LRS]) (27), and consider briefly the prospects and sites of action of the most successful therapeutic agents used to address LRH and dLRH.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abe, K., N. Irokawa, H. Aoyagi, M. Seino, M. Yasujima, K. Ritz, T. Ito, S. Chiba, Y. Sakurai, K. Saito, T. Kusaka, Y. Otsuka, S. Miyazaki, and K. Yoshinaga. Low renin hypertension: is it a stage of essential hypertension? Tohoku J. Exp. Med. 121: 347–354, 1977.
Bailey, C. C., O. T. Bailey, and R. S. Leech. Alloxan diabetes with diabetic complications. N. Engl. J. Med. 230: 533–536, 1944.
Barajas, L. The development and ultrastructure of the juxtaglomerular cell granule. J. Ultrastruct. Res. 15: 400–413, 1966.
Bartter, F. C., P. Pronoue, J. R. Gill, R. C. McCardle. Hyperplasia of the juxtaglonerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am. J. Med. 33: 811–828, 1962.
Beretta-Picesli, C., P. Weidmann, W. Ziegler, Z. Gluck, and G. Kensch. Plasma catecholamines and renin in diabetes mellitus: relationships with posture, age, sodium, and blood pressure. Klin. Wochenschr. 57: 681–691, 1979.
Bouhnik, J., F. X. Galen, E. C. Clauser, J. Menard, and P. Corvol. The renin-angiotensin system in thyroidectomized rats. Endocrinology 108: 647–650, 1981.
Brunner, H. R., J. Nussberger, and B. Waeber. Responsiveness of renin secretion: a key mechanism in the maintenance of blood pressure. J. Hypertens. 4 (Suppl. 4): S89 - S94, 1986.
Burden, A. C., and H. Thurston. Plasma renin activity in diabetes mellitus. Clin. Sci. 56: 255–259, 1979.
Channick, B. J., E. V. Adlin, A. D. Marks. Suppressed plasma renin activity in hypertension. Arch. Intern. Med. 123: 131–140, 1969.
Chatel, R. D., P. Weidmann, J. Flammer, W. H. Ziegler, C. Beretta-Piccoli, W. Vetter, and F. C. Reubi. Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int. 12: 412–421, 1977.
Christlieb, A. R. Diabetes and hypertensive vascular disease. Am. J. Cardiol. 32: 59 2606, 1976.
Christlieb, A. R. Renin-angiotensin-aldosterone system in diabetes mellitus. Diabetes 25 (Suppl. 2): 820–825, 1976.
Christlieb, A. R. Renin, angiotensin, and norepinephrine in alloxan diabetes. Diabetes 23: 962–970, 1974.
Christlieb, A. R., A. Kaldany, J. A. D’Elia. Plasma renin activity and hypertension in diabetes mellitus. Diabetes 25: 969–974, 1976.
Christlieb, A. R., A. Kaldany, J. A. D’Elia, and G. H. Williams. Aldosterone responsiveness in patients with diabetes mellitus. Diabetes 27: 732–737, 1978.
Chrysant, S. G., K. Danisa, D. C. Kern, B. L. Dillard, W. J. Smith, and E. D. Frohlich. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1: 136–141, 1979.
Cohen, A. J., P. Laurens, and J. C. S. Fray. Suppression of renin secretion by insulin: dependence on extracellular calcium. Am. J. Physiol 245 (Endocrinol Metab. 8): E531 - E534, 1983.
Cohen, A. J., K. McCarthy, R. R. Rossetti. Renin secretion by the spontaneously diabetic rat. Diabetes 35: 341–346, 1986.
Cooper, R. S., and J. L. Borke. Intracellular ions and hypertension in blacks. In: Pathophysiology of Hypertension in Blacks, edited by J. C. S. Fray and J. G. Douglas. Oxford University Press, New York, 1992.
Deleiva, A., A. R. Christlieb, J. C. Melby, C. A. Graham, R. P. Day, J. A. Luetscher, and R. G. Zager. Big renin and biosynthetic defect of aldosterone in diabetes mellitus. N. Engl. J. Med. 295: 639–643, 1976.
Derky, F. H. M., G. J. Wenting, A. J. ManI’TVeld, R. P. Verhoeven, and M. A. D. H. Schalekamp. Evidence for activation of circulating inactive renin by the human kidney. Clin. Sci. 56: 115–120, 1979.
Dunn, M. J., and R. L. Tannen. Low-renin hypertension. Kidney Int. 5: 317–325, 1974.
Fagard, R., A. Amery, T. Reybrouck, P. Lijnen, L. Billiet, and J. V. Jossens. Plasma renin levels and systemic haemodynamics in essential hypertension. Clin. Sci. Molec. Med. 52: 591–597, 1977.
Franken, A. A. M., F. H. M. Derky, A. J. ManI’tVeld, W. C. J. Hop, G. H. Rens, E. Peperkamp, P. T. V. M. Dejohn, and M. A. D. H. Schalekamp. High plasma prorenin in diabetes mellitus and its correlation with some complications. J. Clin. Endocrinol. Metab. 71: 1008–1015, 1990.
Fray, J. C. S. Mechanism of increased renin release during sodium deprivation. Am. J. Physiol. 234 (Renal Fluid Electrolyte Physiol. 4): F376 - F380, 1978.
Fray, J. C. S. Stimulus-secretion coupling of renin: role of hemodynamic and other factors. Circ. Res. 47: 485–492, 1980.
Fray, J. C. S. Regulation of renin secretion by calcium and chemiosmotic forces: (patho) physiological considerations. Biochim. Biophys. Acta 1097: 243–262, 1991.
Fray, J. C. S. Subcellular dysregulation of renin and prorenin expression in black essential and diabetic hypertensives. Ethnicity Dis. 2: 142–157, 1992.
Fray, J. C. S., and D. J. Lush. Stretch receptor hypothesis for renin secretion: the role of calcium. J. Hypertens. 2 (Suppl. 1): 19–23, 1984.
Fray, J. C. S., D. J. Lush, C. S. Park. Interrelationship of blood flow, juxtaglomerular cells, and hypertension: role of physical equilibrium and Ca. Am. J. Physiol. 251 (Regulatory Fluid Electrolyte Physiol. 20): R643 - R662, 1986.
Fray, J. C. S., and P. V. H. Mayer. Decreased plasma refill activity and renin release in rats with phaeochromocytoma. Clin. Sci. Molec. Med. 53: 447–452, 1977.
Fray, J. C. S., C. S. Park, and A. N. D. Valentine. Calcium and the control of renin secretion. Endocr. Rev. 8: 53–93, 1987.
Fray, J. C. S., and S. M. Russo. Mechanism for low renin in blacks: studies in hypophysectomised rat model. J. Hum. Hypertens. 4: 160–162, 1990.
Ginesi, L. M., K. A. Munday, and A. R. Noble. Secretion control for active and inactive renin: effects of calcium and potassium on rabbit kidney cortex slices. J. Physiol. 344: 453–463, 1983.
Gossain, V. V., E. E. Werk, L. J. Sholiton, L. Srivastava, and H. C. Knowles. Plasma renin activity in juvenile diabetes mellitus and effect of diazoxide. Diabetes 28: 833–835, 1975.
Grim, C. E., F. C. Luft, N. S. Fineberg, and M. H. Weinberger. Responses to volume expansion and contraction in categorized hypertensive and normotensive man. Hypertension 1: 476–485, 1979.
Grim, C. E., and T. W. Wilson. Salt, slavery and survival: physiological principles underlying the evolutionary hypothesis of salt sensitive hypertension in Western Hemisphere blacks. In: Pathophysiology of Hypertension in Blacks, edited by J. C. S. Fray and J. G. Douglas. Oxford University Press, New York, 1992.
Gross, F., A. J. Vander, R. D. Bunag, and G. M. C. Masson. Renin content of kidneys. In: Renal Hypertension, edited by I. E. Page and J. W. McCubbin. Year Book Publishers, Chicago, 1968, pp. 118–133.
Haddy, F. J. Sodium-potassium pump in low-renin hypertension. Ann. Intern. Med. 93 (part 2): 781–784, 1983.
Helmer, O. M. The renin-angiotensin system and its relation to hypertension. Progr. Cardiovasc. Dis. 8: 117–128, 1965.
Holland, O. B., C. Gomez-Sanchez, C. Fairchild, and N. M. Kaplan. Role of renin classification for diuretic treatment of black hypertensive patients. Arch. Intern. Med. 139: 1365–1370, 1979.
Hsueh, W. A. Potential effects of renin activation on the regulation of renin production. Am. J. Physiol. 247 (Renal Fluid Electrolyte Physiol. 16): F205 - F212, 1984.
Hsueh, W. A., E. J. Carlson, and V. J. Dzau. Characterization of inactive renin from human kidney and plasma. J. Clin. Invest. 71: 506–517, 1983.
Ikemoto, F., K. Takaori, H. Iwao, and K. Yamamoto. Intrarenal localization of renin binding substance in rats. Life Sci. 31: 1011–1016, 1982.
Inoue, H., K. Fukui, S. Takahashi, and Y. Miyake. Molecular cloning and sequence analysis of a CDNA encoding a procine kidney renin-binding protein. J. Biol. Chem. 265: 6556–6561, 1990.
Itoh, S., M. Tanaka, F. Ikemoto, K. Yamamoto, N. Morita, and K. Okamoto. Renal highmolecular-weight renin: unusual formation in the aged stroke-prone spontaneously hypertensive rats. Renal Physiol. 9: 177–186, 1986.
Jose, A., J. R. Crout, and N. M. Kaplan. Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system. Ann. Intern. Med. 72: 9–16, 1970.
Katayama, S., and J. B. Lee. Hypertension in experimental diabetes mellitus: renin-prostaglandin interaction. Hypertension 7: 554–561, 1985.
Kelly, R. B. Pathways of protein secretion in eukaryotes. Science 230: 25–32, 1985.
Kikkawa, R., E. Kitamura, Y. Fujiwara, M. Haneda, and Y. Shigeta. Biphasic alteration of renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. Renal Physiol. 9: 187–192, 1986.
Kotchen, T. A., W. J. Welch, J. N. Lorenz, and C. E. Ott. Renal tubular chloride and refill release. J. Lab. Clin. Med. 110: 533–540, 1987.
Kurtz, A. Cellular control of renin secretion. Rey. Physiol. Biochem. Pharmacol. 113: 140, 1989.
Kurtz, A., and R. Penner. Angiotensin II induces oscillations of intracellular calcium and blocks anomalous inward rectifying potassium current in mouse renal juxtaglomerular cells. Proc. Natl. Acad. Sci. U.S.A. 86: 3423–3427, 1989.
Laragh, J. H. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am. J. Med. 55: 261–274, 1973.
Levy, S. B., L. B. Talner, M. N. Coel, R. Holle, and R. A. Stone. Renal vasculature in essential hypertension: racial differences. Ann. Intern. Med. 88: 12–16, 1978.
Lilley, J. J., L. Hsu, and R. A. Stone. Racial disparity of plasma volume in hypertensive man. Ann. Intern. Med. 84: 707–708, 1976.
Lowder, S. C., P. Hamet, and G. W. Liddle. Contrasting effects of hypoglycemia on plasma renin activity and cyclic adenosin 3’,5’-monophosphate (cyclic AMP) in low renin and normal refill essential hypertension. Circ. Res. 38: 105–108, 1976.
Mitas, J. A., R. Holle, S. B. Levey, and R. A. Stone. Racial analysis of the volume-renin relationship in human hypertension. Arch. Intern. Med. 139: 157–160, 1979.
Morris, B. J. New possibilities for intracellular renin and inactive renin now that the structure of the human renin gene has been elucidated. Clin. Sci. 71: 345–355, 1986.
Murakami, K., S. Chino, S. Hirose, and J. Higaki. Specificity and localization of reninbinding protein(s). Biomed. Res. 1: 476–481, 1980.
Nakamaru, M., T. Ogihara, J. Higaki, K. Masuo, H. Ikegami, K. Shima, and Y. Kumahara. Plasma inactive renin in diabetic patients with neuropathy: a role for the sympathetic nervous system in the conversion in vivo of inactive renin. Acta Endocrinol. 104: 216221, 1983.
Nakamura, R., T. Saruta, K. Yamagami, I Saito, K. Kondo, S. Matsuki. Renin and the juxtaglomerular apparatus in diabetic nephropathy. J. Am Geriatr. Soc. 26: 17–21, 1978.
Nakane, H., Y. Nakane, P. Corvol, and J. Menard. Sodium balance and renin regulation in rats: role of intrinsic renal mechanisms. Kidney Int. 17: 607–614, 1980.
New, M. I. The role of steroid hormones in the development of low-renin hypertension in childhood. NHLBI Workshop on Juvenile Hypertension, May, pp. 283–304, 1983.
Nishimura, K., F. Alhenc-Gelas, A. White, and E. G. Erdos. Activation of membrane-bound kallikrein and renin in the kidney. Proc. Natl. Acad. Sci. U.S.A. 77: 4975–4978, 1980.
Nishimura, K., P. Ward, and E. G. Erdos. Kallikrein and renin in the membrane fractions of the rat kidney. Hypertension 2: 538–545, 1980.
Nugent, C. A. Varieties of low renin hypertension. Milit. Med. 141: 519–522, 1977.
Ogawa, K., M. Matsunaga, H. Nagai, A. Hara, C. H. Pak, and C. Kawai. Effects of enalapril maleate on plasma level of inactive renin in renovascular hypertension. Clin. Exp. Hypertens. [A] A7: 995–1005, 1985.
Ogawa, K., C. Nagai, C. H. Pak, C. Kawai, M. Matsunaga, and A. Hara. Studies on the active and inactive renin in reovascular hypertension. Clin. Exp. Hypertens. [A] A6: 1641–1651, 1984.
Palade, G. Intracellular aspects of the process of protein synthesis. Science 189: 347–358, 1975.
Park, C. S., P. S. Doh, R. E. Carraway, G. C. Chung, J. C. S. Fray, and T. B. Miller. Stimulation of renin secretion by ethacrymc acid is independent of Na -K -2C1- cotransport. Am. J. Physiol. 259: (Renal Fluid Electrolyte Physiol. 28): F539 - F544, 1990.
Park, C. S., T. W. Honeyman, E. S. Chung, J. S. Lee, D. H. Sigmon, and J. C. S. Fray. Involvement of calmodulin in mediating inhibitory action of intracellular Cat+ on renin secretion. Am. J. Physiol. 251 (Renal Fluid Electrolyte Physiol. 20): F1055 - F1062, 1986.
Pedrinelli, R., A. Clerico, L. Graziadei, S. Teddei, M. D. Chicca, and A. Saluetti. Lack of evidence for NaK-ATPase inhibitor as a cause of low renin human hypertension. J. Hypertens. 4 (Suppl. 6): 340–342, 1986.
Pedrinelli, R., S. Taddei, L. Graziadei, and A. Salvetti. Vascular responses to ouabain and norepinephrine in low and normal renin hypertension. Hypertension 8: 786–792, 1986.
Perez, G. O., L. Lespier, J. Jacobi, J. R. Oster, F. H. Katz, C. A. Vaamonde, and L. M. Fishman. Hyporeninemia and hypoadosteronism in diabetes mellitus. Arch. Intern. Med. 137: 825–855, 1977.
Pinet, F., J. Mizrahi, I. Laboulandine, J. Menard, and P. Corvol. Regulation of prorenin secretion in cultured human transfected juxtaglomerular cells. J. Clin. Invest. 80: 724–731, 1987.
Pratt, R. E., J. E. Carleton, J. P. Richie, C. Heusser, and V. J. Dzau Human renin biosynthesis and secretion in normal and ischemic kidneys. Proc. Natl. Acad. Sci. U.S.A. 84: 7837–7840, 1987.
Pratt, J. H., C. A. Parkinson, M. H. Weinberger, and W. C. Duckworth. Decreases in renin and aldosterone secretion in alloxan diabetes: an effect of insulin deficiency. Endocrinology 116: 1712–1716, 1985.
Purdon, A. D., A. Y. Loh, and D. H. Osmond. Renin substrate (angiotensinogen) preparations in the determination of prorenin and renin: evidence for extrarenal plasma prorenin and its renal “convertase.” Can. J. Physiol. Pharmacol. 65: 2319–2328, 1987.
Rapp J. P., and S.-M. Wang. Genetic hypertension: classical and molecular genetic concepts as applied to the renin gene. In: Hypertension, edited by J. H. Laragh and B. M. Brenner. Raven Press, New York, 1990, pp. 955–964.
Resnick, L. M., and J. H. Laragh. Renin, calcium metabolism and the pathophysiologic basis of antihypertensive therapy. Am. J. Cardiol. 56: 68H - 74H, 1985.
Richards, H. K., D. J. Lush, A. R. Noble, and K. A. Munday. Inactive renin in rabbit plasma: effect of furosemide. Clin. Sci. 60: 393–398, 1981.
Rouiller, C., and L. Orci. The structure of the juxtaglomerular complex. In: The Kidney, Morphology, Biochemistry, Physiology, Vol. 4, edited by C. Rouiller and A. F. Muller. Academic Press, New York, 1971, pp. 1–80.
Sadoff, L. Neprotoxicity of streptozotocin. Cancer Chemother. 54: 457–459, 1970.
Sagnella, G. A., P. R. B. Caldwell, and W. S. Peart. Subcellular distribution of low-and high-molecular-weight renin and its relation to a renin inhibitor in pig renal cortex. Clin. Sci. 59: 337–345, 1980.
Sakamoto, W., K. Yoshikawa, A. Yokoyama, M. Kohri, H. Handa, S. Ueham, A. Hirayama, and H. Izumi Glandular kallikrein, renin and tonin in tissues of diabetic and hypertensive rats. J. Clin. Chem. Clin. Biochem. 24: 437–440, 1986.
Saunders, E. Hypertension in blacks. Med. Clin. North Am. 71: 1013–1029, 1987.
Schalekamp, M. A., M. Lebel, D. G. Beevers, R. Fraser, G. Kolster, and W. H. Birkenhager. Body fluid-volume in low-renin hypertension. Lancet 1: 310–311, 1974.
Schalekamp, M. A. D. H., M. P. A. Schalekamp-Kuyken, and W. H. Birkenhager. Abnormal renal haemodynamics and renin suppression in hypertensive patients. Clin. Sci. 38: 101–110, 1970.
Sealey, J. E., S. A. Atlas, and J. H. Laragh. Prorenin and other large molecular weight forms of renin. Endocr. Rev. 1: 365–391, 1980.
Sealey, J. E., and J. H. Laragh. Searching out low renin patients: limitations of some commonly used methods. Am. J. Med. 55: 303–313, 1973.
Sigmon, D. H., and J. C. S. Fray. Chemiosmotic control of renin release from isolated renin granules of rat kidneys. J. Physiol. (Lond.) 436: 237–256, 1991.
Simon, C. D., T. W. Honeyman, and J. C. S. Fray. Renin-angiotensin system in hypophysectomized rats. I. Control of blood pressure. Am. J. Physiol. 246 (Endocrinol. Metab. 10) E84 — E88, 1984.
Simon, S. M., and G. Blobel. A protein-conducting channel in the endoplasmic reticulum. Cell 65: 371–380, 1991.
Skott, O. Do osmotic forces play a role in renin secretion? Am. J. Physiol. 255 (Renal Fluid Electrolyte Physiol 24) Fl—F10,1988.
Skott, O., and R. Taugner. Effects of extracellular osmolality on renin release and on the ultrastructure of the juxtaglomerular epitheloid cell granules. Cell Tissue Res. 249: 325–329, 1987.
Sommer, S. C., and J. Melamed. Renal pathology of essential hypertension. Am. J. Hypertens. 3: 583–587, 1990.
Sullivan, P. A., M. Kelleher, M. Twomey, and M. Dineen. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension. J. Hyper-tens. 3: 359–363, 1985.
Swales, J. D. Low-renin hypertension: nephrosclerosis? Lancet 2: 75–77, 1975.
Thurston, H., and J. D. Swales. Low renin hypertension: a distinct entity. Lancet 2: 930932, 1976.
Tuek, M. L., M. P. Sambhi, and L. Levin. Hyporeninemic hypoaldosteronism in diabetes mellitus: studies of the autonomic nervous system’s control of renin release. Diabetes 28: 237–241, 1979.
Ueno, N., H. Miyazaki, S. Hirose, and K. Murakami. A 56,000-dalton renin-binding protein in hog kidney is an endogenous renin-inhibitor. J. Biol. Chem. 256: 12023–12027, 1981.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Urinary and serum electrolytes in untreated black and white hypertensives. J. Chronic Dis. 40: 839–847, 1987.
Vlahos, C. J., J. D. Walls, D. T. Berg, and B. W. Grinnell. The purification and characterization of recombinant human renin expressed in the human kidney cell line 293. Biochem. Biophys. Res. Comm. 171: 375–383, 1990.
Wilson, D. M., and J. A. Luetscher. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N. Engl. J. Med. 323: 1101–1106, 1990.
Wright, J. T., and J. G. Douglas. Drug therapy in black hypertensives. In: Pathophysiology of Hypertension in Blacks, edited by J. C. S. Fray and J. G. Douglas. Oxford University Press, New York, 1992.
Yamamoto, K., and F. Ikemoto. High molecular-weight renin and renin-binding protein. Trends Pharmacol. Sci. 4: 381–383, 1983.
Zidek, W., C. Karoff, H. Losse, and H. Vetter. Weight reduction and salt restriction in hypertension: effects on blood pressure and intracellular electrolytes. Klin. Wochenschr. 64: 1183–1185, 1986.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 American Physiological Society
About this chapter
Cite this chapter
Fray, J.C.S. (1993). (pro)Renin Processing and Secretion in Black Essential Hypertension and Other Low-Renin Syndromes. In: Fray, J.C.S., Douglas, J.G. (eds) Pathophysiology of Hypertension in Blacks. Clinical Physiology Series. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7577-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7577-4_10
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-7577-4
eBook Packages: Springer Book Archive